Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)

NCT00247559 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00247559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00247559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
April 8, 2005
Enrollment
221 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lateral canthal lines